世界のバイオシミラー市場動向と予測(~2018):Updated Version...市場調査レポートについてご紹介

【英文タイトル】Biosimilars Market Product [Recombinant Non-Glycosylated Proteins (Insulin, Filgrastim, Somatropin), Glycosylated (Monoclonal Antibodies, Erythropoietin), Peptides (Glucagon, Calcitonin)] & Application (Oncology, Blood Disorders) - Global Forecast to 2018

▼当市場調査レポートの詳細内容確認、お問い合わせ及びご購入申込は下記ページでお願いします。▼マーケットレポート

【レポートの概要(一部)】

Table Of Contents

1 Introduction (Page No. – 26)
1.1 Objectives Of The Study
1.2 Report Description
1.3 Markets Covered
1.4 Stakeholders
1.5 Market Scope
1.6 Research Methodology
1.6.1 Market Size Estimation And Data Triangulation
1.6.2 Market Share
1.6.3 Key Data Points From Secondary Sources
1.6.4 Key Data Points From Primary Sources
1.6.5 Assumptions

2 Executive Summary (Page No. – 38)

3 Premium Insights (Page No. – 42)
3.1 Biosimilars Market Vs. Biologic Market
3.2 Global Biosimilars Market
3.2.1 Market Dynamics
3.2.2 Product Market
3.2.3 Application Market
3.3 Geographic Analysis, By Country
3.4 Market Share Analysis

4 Market Overview (Page No. – 49)
4.1 Introduction
4.2 Evolution
4.3 Market Segmentation
4.4 Market Dynamics
4.4.1 Drivers
4.4.1.1 Growing Pressure To Cut Healthcare Expenditure, An Impetus To The Demand Of Biosimilars
4.4.1.2 Off-Patent Biologic Products To Boost The Biosimilars Market
4.4.1.3 Rise In Aging Population Triggers The Incidences Of Chronic Disorders And Thus Boosts The Biosimilars Market
4.4.1.4 Growing Demand For Biosimilars Drugs Due To Their Cost Effectiveness
4.4.1.5 Rising Incidences Of Various Diseases To Boost The Biosimilars Market
4.4.1.6 Strategic Collaborations Lead To Increased Productivity And Clinical Trial Activities For Biosimilars
4.4.1.7 Government Support And Initiatives Propel The Biosimilars Market
4.4.2 Restraints
4.4.2.1 High Manufacturing Complexities And Costs, A Significant Entry Barrier For Companies
4.4.2.2 Stringent Regulatory Requirements In Countries To Adversely Affect Investments In Biosimilars
4.4.2.3 Innovative Strategies By Biologic Drug Manufacturers To Restrict Entry Into The Biosimilars Market
4.4.3 Opportunities
4.4.3.1 Emerging Countries
4.4.3.2 Untapped Indications
4.4.4 Challenges
4.4.4.1 Requirement Of Complex Infrastructure For Manufacturing As Well As Extensive Clinical Trials For Obtaining Approval
4.4.4.2 Bulk Production To Meet Market Demand Is A Challenge For Smaller Manufacturers
4.5 Winning Imperatives
4.5.1 Partnerships & Agreements To Gain Competitive Advantage
4.5.2 Sandoz’s In-House Capabilities Made It The Global Leader
4.6 Burning Issues
4.6.1 Opportunities For New Entrants In The Biosimilars Market
4.6.2 Product Withdrawals Provide Significant Opportunities For New Entrants
4.6.3 Termination Of Joint Ventures Allows Companies To Focus On Core Competencies
4.6.4 Discontinuation Of Patent By Roche Provides Opportunities To Other Players
4.7 Biosimilars Pipeline Analysis
4.7.1 About 50 Biosimilars Of Monoclonal Antibody In The Pipeline

5 Industry Analysis (Page No. – 82)
5.1 Introduction
5.2 Research & Development Investment Analysis
5.3 Industry Trend Analysis
5.3.1 Forthcoming Patent Expirations
5.3.2 Manufacturing Agreement
5.4 Porter’s Five Forces Analysis
5.4.1 Threat Of New Entrants
5.4.2 Threat Of Substitutes
5.4.3 Competitor Rivalry
5.4.4 Bargaining Power Of Suppliers
5.4.5 Bargaining Power Of Buyers

6 Global Biosimilars Market, By Product (Page No. – 90)
6.1 Introduction
6.1.1 Biosimilars Demand To Grow Owing To High Efficacies & Low Prices
6.2 Recombinant Non-Glycosylated Proteins
6.2.1 Insulin Biosimilars Will Drive The Recombinant Non-Glycosylated Proteins Segment
6.2.2 Insulin
6.2.2.1 Insulin Glargine, Lispro, And Aspart Will Go Off-Patent In 2014
6.2.3 Recombinant Human Growth Hormone (RHGH)
6.2.4 Granulocyte Colony-Stimulating Factor (Filgrastim)
6.2.4.1 Strong Biosimilars Pipeline To Boost The Filgrastim Market
6.2.5 Interferons
6.2.5.1 Biosimilars Of Interferon Available Only In Asia-Pacific And Row Regions Due To Less Stringent Regulatory Pathway
6.3 Recombinant Glycosylated Proteins
6.3.1 Erythropoietin (EPO)
6.3.1.1 Cost Effectiveness Of Epo Biosimilars, One Of The Major Driving Factors
6.3.2 Monoclonal Antibodies (MAB)
6.3.2.1 Monoclonal Antibodies Market, A Lucrative Opportunity For Companies
6.3.3 Follitropin
6.3.3.1 New Biosimilars Of Follitropin ‘Ovaleap’ Received Marketing Authorization In Europe In 2014
6.4 Recombinant Peptides
6.4.1 Glucagon
6.4.1.1 Glucagen, The First Fop Approved In U.S.
6.4.2 Calcitonin
6.4.2.1 U.S. Fda Does Not Support Miacalcin As A Treatment For Osteoporosis

7 Global Biosimilars Market, By Application (Page No. – 122)
7.1 Introduction
7.2 Oncology
7.2.1 Growing Cost Burden Of Cancer Will Stimulate The Demand For Mabs & Filgrastim
7.3 Blood Disorders
7.3.1 Rise In Incidences Of Anemia, Leukemia, Myeloma & Lymphoma Will Enhance The Need For Biosimilars
7.4 Chronic And Autoimmune Diseases
7.4.1 Monoclonal Antibodies To Boost The Application Of Biosimilars In Autoimmune Diseases
7.5 Growth Hormone Deficiency
7.5.1 About 10,000 New Patients Are Diagnosed Annually With Growth Hormonal Disorders
7.6 Infectious Diseases
7.6.1 Growing Cases Of Hepatitis, A Boost For The Interferon Biosimilars Market
7.7 Others (Female Infertility, Hypoglycaemia, Myocardial Infarction, Postmenopausal Osteoporosis & Chronic Kidney Failure)

8 Global Biosimilars Service Market (Page No. – 138)
8.1 Introduction
8.1.1 R&D And Manufacturing Issues Provide Significant Opportunities To CRO & CMO
8.2 Contract Manufacturing Organizations
8.2.1 CMO Provide Considerable Opportunities To Companies Planning To Enter Biosimilars Market
8.3 Contract Research Organizations
8.3.1 Lack Of Expertise With The Biosimilars Players, A Prospect For Cro
8.4 Others (Non-Clinical & Bioinformatics)

9 Geographic Analysis (Page No. – 148)
9.1 Introduction
9.1.1 Europe Dominates The Global Biosimilars Market Due To Its Well Defined Regulatory Guidelines
9.2 North America
9.2.1 Rise In Pressure To Cut Healthcare Cost & A Leading Biologic Market Will Increase The Demand For Low Priced Biosimilars
9.2.2 Regulatory Outlook
9.2.2.1 U.S.
9.2.2.2 Canada
9.2.3 Market Analysis
9.2.3.1 U.S.
9.2.3.1.1 Financial Support By U.S. Government To FDA For Review Of Biosimilars Will Add Significant Growth To Biosimilars Industry
9.2.3.2 Canada
9.3 Europe
9.3.1 Europe Is The Pioneer For The Development Of Biosimilars
9.3.2 Regulatory Outlook
9.3.3 Market Analysis
9.3.3.1 U.K.
9.3.3.1.1 Well-Developed Generics Market & Growing Pressure To Decrease Drug Prices To Drive The Biosimilars Market
9.3.3.2 Germany
9.3.3.2.1 Reference Pricing System Of Germany Leads To Faster Adoption Of Biosimilars
9.3.3.3 France
9.3.3.3.1 Biosimilars Not Considered As Generic Drugs & Are Excluded From The French Substitution List
9.3.3.4 Spain
9.3.3.4.1 Effect Of Recession On Branded Drugs Will Shift The Market Towards Biosimilars Drugs
9.3.3.5 Italy
9.3.3.5.1 Adoption Of Biosimilars Low Compared To Branded Versions
9.3.3.6 Rest Of Europe (ROE)
9.3.3.6.1 Substitution Status Varies In Different Countries
9.3.3.6.2 Reference Pricing System Of Denmark Will Proliferate The Biosimilars Market
9.4 Asia-Pacific
9.4.1 APAC, A Blue-Eyed Market For Investors In Biosimilars Owing To Less Stringent Regulatory Pathway
9.4.2 Growing Medical Tourism & Low Manufacturing Cost Will Propel The Biosimilars Market
9.4.3 Regulatory Outlook
9.4.3.1 China
9.4.3.2 India
9.4.3.3 Japan
9.4.3.4 South Korea
9.4.4 Market Analysis
9.4.4.1 China
9.4.4.1.1 Lack Of Government Regulation & Low Ip Protection For Biologic Compounds Will Drive The Biosimilars Market
9.4.4.2 India
9.4.4.2.1 Semi-Regulatory Environment For Approving Similar Biologic Drugs Propels The Biosimilars Market
9.4.4.3 Japan
9.4.4.4 South Korea
9.4.4.4.1 Government Support & Strong Biosimilar Pipeline, An Impetus To The Biosimilars Market
9.4.4.5 Rest Of Asia-Pacific (ROAP)
9.4.4.5.1 Australia & Malaysia To Aggressively Promote The Adoption Of Biosimilars
9.5 Rest Of The World (ROW)
9.5.1 Latam Provides High Growth Opportunities For Biosimilars Player
9.5.2 Regulatory Outlook
9.5.2.1 Brazil
9.5.2.2 Mexico
9.5.2.3 Argentina
9.5.2.4 Saudi Arabia
9.5.3 Market Analysis
9.5.3.1 Latin America
9.5.3.1.1 Strong Economic Condition & Government Support Will Strengthen The Biosimilar Industry In Brazil
9.5.3.2 Africa
9.5.3.3 Middle East

10 Competitive Landscape (Page No. – 218)
10.1 Introduction
10.1.1 Agreements & Partnerships Was The Key Strategy Adopted By Biosimilar Players
10.2 Market Share Analysis
10.3 Agreements, Joint Ventures, Partnerships, & Collaborations
10.4 Acquisitions
10.5 New Product Launches
10.6 Others (Regulatory Approvals)

11 Company Profiles (Overview, Financials, Products & Services, Strategy, & Developments)* (Page No. – 238)
11.1 Actavis, Inc.
11.2 Amgen, Inc.
11.3 Biocon Ltd.
11.4 Celltrion, Inc.
11.5 Cipla Ltd.
11.6 Dr. Reddy’s Laboratories Ltd.
11.7 Emcure Pharmaceuticals Ltd.
11.8 Hospira, Inc.
11.9 Lg Life Sciences Ltd.
11.1 Merck Kgaa
11.11 Mylan, Inc.
11.12 Ranbaxy Laboratories Ltd.
11.13 Roche Holding Ltd.
11.14 Sandoz International GMBH (Division Of Novartis International Ag)
11.15 Stada Arzneimittel Ag
11.16 Synthon
11.17 Teva Pharmaceutical Industries Ltd.
11.18 Wockhardt Ltd.

*Details On Financials, Product & Services, Strategy, & Developments Might Not Be Captured In Case Of Unlisted Companies.


【レポート販売概要】

■ タイトル:世界のバイオシミラー市場動向と予測(~2018):Updated Version
■ 英文:Biosimilars Market Product [Recombinant Non-Glycosylated Proteins (Insulin, Filgrastim, Somatropin), Glycosylated (Monoclonal Antibodies, Erythropoietin), Peptides (Glucagon, Calcitonin)] & Application (Oncology, Blood Disorders) - Global Forecast to 2018
■ 発行日:2013年11月
■ 調査会社:MarketsandMarkets
■ 商品コード:BT 2160
■ 調査対象地域:グローバル
  • エレクトロクロミック・ガラス及びフィルムの世界市場
    Electrochromic (EC) glass is already being used in considerable quantities for smart mirrors by Gentex, but NanoMarkets believes that EC glass also has considerable opportunities going forward in the smart windows market. Indeed, of the half-dozen technologies that are currently being aimed at the emerging smart windows sector, it seems likely that EC glass will do the best in the marketplace. Thi …
  • ヨーロッパのファイバレーザ市場2015-2019
    Fiber lasers contain active gain medium, an optical fiber integrated with rare-earth elements such as erbium and ytterbium. Unlike conventional gas lasers, a fiber laser uses part of the fiber as the resonating cavity where the laser action takes place to generate laser beams. Fiber lasers are preferred over other lasers such as CO2 lasers as they are more reliable, efficient, robust, and portable …
  • 遅発性ジスキネジア(Tardive Dyskinesia):世界の治験レビュー(2015年上半期版)
    Tardive Dyskinesia Global Clinical Trials Review, H1, 2015 Summary GlobalData's clinical trial report, “Tardive Dyskinesia Global Clinical Trials Review, H1, 2015" provides data on the Tardive Dyskinesia clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Tardive Dyskinesia. It includes an overview of the trial numbers and their recruitme …
  • スペインの感染症検査市場2014
    This report provides an overview of the Spanish infectious disease diagnostics market, including market shares of leading suppliers by test, as well as volume and sales forecasts by market segment. Table of ContentsBusiness EnvironmentMarket Structure  Market Size, Growth, and Major Suppliers' Market SharesList of Tables            & …
  • Monoclonal Antibodies Market in Gastric and Esophageal Cancers to 2019 – Crowded Late-Stage Pipelines and Favorable Market Conditions Encourage Robust Growth
    Monoclonal Antibodies Market in Gastric and Esophageal Cancers to 2019 - Crowded Late-Stage Pipelines and Favorable Market Conditions Encourage Robust Growth Summary GBI Research has released the pharma report “Monoclonal Antibodies Market in Gastric and Esophageal Cancers to 2019 - Crowded Late-Stage Pipelines and Favorable Market Conditions Encourage Robust Growth” Gastric and esophageal cancers …
  • アズレンの世界市場2015
    Azulene (CAS 275-51-4) Market Research Report 2015 aims at providing comprehensive data on Azulene market globally and regionally (Europe, Asia, North America, Latin America etc.) The report includes Azulene description, covers its application areas, manufacturing methods, patterns. It captures Azulene market trends, pays close attention to Azulene manufacturers and names suppliers. Besides, the r …
  • モバイル仮想ネットワークオペレータ(MVNO)の世界市場分析、セグメント予測、-2010
    The global MVNO market is expected to reach USD 73.20 billion by 2020. Increasing global mobile subscribers and demand for data services is expected to favor market growth over the next six years. MVNOs provide differentiated services to customers by targeting niche market segments such as retail, business, roaming, etc. This helps to avoid direct competition with MNOs and also generates additiona …
  • 世界のエンジニアリングウッド製品市場2015
    The Global Engineered Wood Product Industry Report 2015 is a professional and in-depth study on the current state of the Engineered Wood Product industry. The report provides a basic overview of the industry including definitions, classifications, applications and industry chain structure.The Engineered Wood Product market analysis is provided for the international markets including development tr …
  • FTTxサービス及び価格動向
    n/a
  • 世界の産業用ボイラー市場動向(2012-2016)
    TechNavio’s analysts forecast the Global Industrial Boiler market to grow at a CAGR of 2.82 percent over the period 2012-2016. One of the key factors contributing to this market growth is the increasing demand of industrial boilers from developing countries. The Global Industrial Boiler market has also been witnessing the increasing focus toward R&D activities. However, the need for high investmen …
  • ポーチの世界市場予測・分析2020-2024
    Global Pouches Market: About this market Technavio’s pouches market analysis considers sales from flat pouches, stand-up pouches, spout pouches, and other types. Our study also finds the sales of pouches in APAC, Europe, MEA, North America, and South America. In 2019, the flat pouches segment had a significant market share, and this trend is expected to continue over the forecast period. Factors s …
  • 動物用画像診断装置の世界市場2015-2022
    According to Stratistics MRC, the Global Veterinary Imaging Market is valued at $1.98 billion in 2015 and is expected to grow at a CAGR of 7.1% to reach $3.21 billion by 2022. Increasing demand for diagnostic equipment for the appropriate care of pets is one of the key factors fueling the market growth. Moreover, shift towards oil drilling activities by exploration and production companies due to …
  • 潤滑油の世界市場:鉱油系潤滑油、合成潤滑油、バイオ潤滑油
    About Lubricants Lubricants reduce friction between surfaces. They are usually in oily, semi-fluid, or solid state. Superior-quality lubricants possess various characteristics such as a high level of thermal stability, high boiling point, low freezing point, and high viscosity index. These features help it reduce friction between surfaces of machine parts and increase operational efficiency. There …
  • E911 and NG 911: Expanding Intellectual Property Beyond Emergencies
    Enhanced 911 services is a tight ecosystem. There are a few leaders in control of all key customers. Each lead provider controls a niche that overlaps with other providers. Whilst revenue for most of the leads is secure due to lengthy government contracts, the stock gains are negligible. There are options in portfolio restructuring for the leaders ? acquire or develop new technologies and sales ch …
  • 核医学の世界市場2015-2022
    According to Stratistics MRC, the Global Nuclear Medicine Market is valued at $4.42 billion in 2015 and is expected to grow at a CAGR of 10.55 % to reach $8.92 billion by 2022. Rising demand from emerging nations and the growing incidence of cardiovascular ailments and cancers are some of the key factors driving the market growth. Conversely, strict government regulations and competition from conv …
※当サイトは世界の市場調査レポート紹介サイトです。市場規模、市場動向、市場予測など、多様な分析データを含むグローバル調査レポートをご案内致します。日本国内を含むアジア太平洋、中国、ヨーロッパ、アメリカ、北米、中南米、中東、アフリカ地域などにおける、製品、サービス、技術、企業(メーカー、ベンダー)、市場シェア、市場環境など多様な項目に対応致します。当サイトでご紹介するレポートは「市場調査レポート販売サイトのMarketReport.jp」でお問い合わせ及びご購入可能です。